Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPF5OX)

Drug Name

3PO Drug Info

Synonyms

18550-98-6; 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; (E)-3PO; 13309-08-5; CHEMBL3105848; (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one; (E)-3-(Pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one; SCHEMBL196639; 3-PO; (E)-3PO;3PO; CHEBI:144367; BCP34641; ZINC3997313; BDBM50445948; s7639; 3PO, >=98% (HPLC); AKOS025142053; CCG-266648; CS-5491; SB17190; NCGC00386709-03; AS-55969; HY-19824; AB00079158-01; SR-01000203323; SR-01000203323-1; 2-Propen-1-one, 3-(3-pyridinyl)-1-(4-pyridinyl)-; 3-(pyridin-3-yl)-1-(pyridin-4-yl)prop-2-en-1-one; (2E)-3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one; (E)-3-pyridin-3-yl-1-pyridin-4-ylprop-2-en-1-one (3PO); (2E)-3-(PYRIDIN-3-YL)-1-(PYRIDIN-4-YL)PROP-2-EN-1-ONE

Indication

Disease Entry	ICD 11	Status	REF
Pulmonary fibrosis	CB03.4	Investigative	[1]

Cross-matching ID

PubChem CID: 5720233
ChEBI ID: CHEBI:144367
TTD Drug ID: DMPF5OX

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Renal carcinoma antigen NY-REN-56 (PFKFB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PFK-158	DMIR21F	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Renal carcinoma antigen NY-REN-56 (PFKFB3)	TTTHMQJ	F263_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis. Lab Invest. 2020 Jun;100(6):801-811.
2	CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis. Gastroenterology. 2020 Jul;159(1):273-288.
3	Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib. Cancer Metab. 2014; 2(Suppl 1): P14.